SOURCE: Gene Express, Inc.

October 16, 2007 08:30 ET

Gene Express Appoints Hannah Monds Director of Business Development

TOLEDO, OH--(Marketwire - October 16, 2007) - Gene Express, Inc. today announced the appointment of Hannah Monds to Director of Business Development.

Gerald Vardzel, CEO of Gene Express, commented, "Hannah brings over 12 years of operational, business and consulting experience in pharmaceutical drug development to the Company. She will be responsible for licensing our StaRT-PCR™ technology and managing customer relations among our various business partners. Her vast network of contacts within pharmaceutical and clinical research organizations will assist in Gene Express's commercial development."

Prior to joining Gene Express, Ms. Monds spent more than 10 years with AAIPharma, a global provider of product development and support services to the pharmaceutical, biotechnology, and medical device industries. She began her career at AAIPharma performing laboratory analyses of pharmaceuticals. Ms. Monds then served as Manager of AAIPharma's Stability Management Services division. Here she developed the department's operations and drove the growth of the business unit through customer development and management.

Over the past seven years, Ms. Monds has also performed operational audits and provided consulting services for various pharmaceutical organizations, presented at several conferences regarding the stability of pharmaceuticals throughout the drug development process, and contributed to technical publications. In 2006, Ms. Monds received an M.B.A. from the University of North Carolina at Wilmington.

Ms. Monds stated, "It is an honor to join the Gene Express team, and to work amongst a group of highly experienced professionals in both drug and diagnostic development. I look forward to further developing and managing customer relations, and executing the Company's business strategy."

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug and molecular diagnostic development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information

  • Contact:
    Rachel Levine
    The Global Consulting Group
    Tel: 646-284-9439